Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A dominant-negative therapy for anthrax

Nature Medicine volume 7, pages 659–660 (2001)Cite this article

The oligomeric structure of anthrax toxin might be exploited as a preventative or therapeutic vaccine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structure of anthrax PA toxin.

References

  1. Meselson, M. et al. The Sverdlovsk anthrax outbreak of 1979. Science 266, 1202–1208 (1994).

    Article  CAS  Google Scholar 

  2. Sellman, B.R., Mourez, M. & Collier, R.J. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292, 695–697 (2001).

    Article  CAS  Google Scholar 

  3. Leppla, S.H. Comprehensive Sourcebook of Bacterial Protein Toxins. (eds. Alouf, J.E. & Freer, J.H.) 243–263 (Academic, London, 1999).

    Google Scholar 

  4. Arora, N., Klimpel, K.R., Singh, Y. & Leppla, S.H. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem. 267, 15542–15548 (1992).

    CAS  PubMed  Google Scholar 

  5. Wesche, J., Elliott, J.L., Falnes, P.O., Olsnes, S. & Collier, R.J. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 37, 15737–15746 (1998).

    Article  CAS  Google Scholar 

  6. Petosa, C., Collier, R.J., Klimpel, K.R., Leppla, S.H. & Liddington, R.C. Crystal structure of the anthrax toxin protective antigen. Nature 385, 833–838 (1997).

    Article  CAS  Google Scholar 

  7. Leppla, S.H., Friedlander, A.M. & Cora, E. Bacterial Protein Toxins. (eds. Fehrenbach, F. et al.) 111–112 (Gustav Fischer, New York, 1988).

    Google Scholar 

  8. Sellman, B.R., Nassi, S. & Collier, R.J. Point mutations in anthrax protective antigen that block translocation. J. Biol. Chem. 276, 8371–8376 (2001).

    Article  CAS  Google Scholar 

  9. Vinion-Dubiel, A.D. et al. A dominant negative mutant of Helicobacter pylori vacuolating toxin (VacA) inhibits VacA-induced cell vacuolation. J. Biol. Chem. 274, 37736–37742 (1999).

    Article  CAS  Google Scholar 

  10. Molnar, D.M. & Altenbern, R.A. Alterations in the biological activity of protective antigen of Bacillus anthracis toxin. Proc. Soc. Exp. Biol. Med. 114, 294–297 (1963).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oral Infection and Immunity Branch National Institute of Dental & Craniofacial Research National Institutes of Health, Bethesda, Maryland, USA

    Stephen H. Leppla

Authors
  1. Stephen H. Leppla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leppla, S. A dominant-negative therapy for anthrax. Nat Med 7, 659–660 (2001). https://doi.org/10.1038/89025

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/89025

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing